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Large-scale screening for atrial fibrillation (AF) requires reliable methods to identify at-risk
populations. Using an experimental semi-quantitative biomarker assay, B-type natriuretic
peptide (BNP) and fibroblast growth factor 23 (FGF23) were recently identified as the most
suitable biomarkers for detecting AF in combination with simple morphometric parameters
(age, sex, and body mass index [BMI]). In this study, we validated the AF model using stan-
dardised, high-throughput, high-sensitivity biomarker assays.
Methods and findings
For this study, 1,625 consecutive patients with either (1) diagnosed AF or (2) sinus rhythm
with CHA2DS2-VASc score of 2 or more were recruited from a large teaching hospital in Bir-
mingham, West Midlands, UK, between September 2014 and February 2018. Seven-day
ambulatory ECG monitoring excluded silent AF. Patients with tachyarrhythmias apart from
AF and incomplete cases were excluded. AF was diagnosed according to current clinical
guidelines and confirmed by ECG. We developed a high-throughput, high-sensitivity assay
for FGF23, quantified plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) and
FGF23, and compared results to the previously used multibiomarker research assay. Data
were fitted to the previously derived model, adjusting for differences in measurement
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platforms and known confounders (heart failure and chronic kidney disease). In 1,084
patients (46% with AF; median [Q1, Q3] age 70 [60, 78] years, median [Q1, Q3] BMI 28.8
[25.1, 32.8] kg/m2, 59% males), patients with AF had higher concentrations of NT-proBNP
(median [Q1, Q3] per 100 pg/ml: with AF 12.00 [4.19, 30.15], without AF 4.25 [1.17, 15.70];
p < 0.001) and FGF23 (median [Q1, Q3] per 100 pg/ml: with AF 1.93 [1.30, 4.16], without AF
1.55 [1.04, 2.62]; p < 0.001). Univariate associations remained after adjusting for heart fail-
ure and estimated glomerular filtration rate, known confounders of NT-proBNP and FGF23.
The fitted model yielded a C-statistic of 0.688 (95% CI 0.656, 0.719), almost identical to that
of the derived model (C-statistic 0.691; 95% CI 0.638, 0.744). The key limitation is that this
validation was performed in a cohort that is very similar demographically to the one used in
model development, calling for further external validation.
Conclusions
Age, sex, and BMI combined with elevated NT-proBNP and elevated FGF23, quantified on
a high-throughput platform, reliably identify patients with AF.
Trial registration
Registry IRAS ID 97753 Health Research Authority (HRA), United Kingdom
Author summary
Why was this study done?
• Atrial fibrillation (AF) is the most commonly sustained arrhythmia in the world,
markedly increasing the risk of stroke, heart failure, and cardiovascular death.
• AF episodes can be transient and go undetected by ECG for a long time, leading to
untreated AF and avoidable complications such as stroke.
• Blood biomarkers are an easy and affordable way to enable screening for undiagnosed,
silent AF.
• An earlier study using a dual-antibody-based research assay identified a simple model,
consisting of age, sex, body mass index, and 2 biomarkers, FGF23 and NT-proBNP, that
identified patients with AF.
What did the researchers do and find?
• We measured 2 biomarkers, NT-proBNP and FGF23, using high-throughput, high-sen-
sitivity assays that are ready for clinical use. The FGF23 assay was developed for this
study.
• We incorporated these biomarkers into a model including age, sex, and body mass
index, which was derived from previous work where research assays were used to iden-
tify biomarkers to detect patients with AF.
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• We demonstrated that the model using the standardised assays performed consistently
to identify patients with AF.
What do these findings mean?
• Elevated concentrations of FGF23 and NT-proBNP, in addition to older age, female sex,
and high body mass index, identify patients who are likely to have AF.
• In the future, point-of-care testing can be easily performed using these biomarkers in
combination with 3 simple pieces of information (age, sex, and body mass index) to tar-
get intensive screening, for example, using ECG monitoring.
Introduction
Improving detection of patients with atrial fibrillation (AF) has the potential to prevent stroke,
premature cardiovascular death, and dementia [1–3], but large-scale ECG screening of entire
populations is difficult to justify, as stated, for example, by the US Food and Drug Administra-
tion (FDA). Targeting ECG screening to populations at risk could render AF screening feasible
and cost-effective [4,5]. B-type natriuretic peptide (BNP) and fibroblast growth factor 23
(FGF23) were previously identified from an initial pool of 92 biomarkers to be strongly associ-
ated with prevalent AF in a cohort of consecutive patients presenting to hospital [6]. These bio-
markers were discovered using both statistical modelling and machine learning techniques
that incorporated processes for biomarker selection and considered key clinical and imaging
parameters alongside biomarkers. We found that the combination of age, sex, and body mass
index (BMI) with BNP and FGF23 was able to discriminate patients with AF from patients in
sinus rhythm [6]. In that study, biomarker concentrations were estimated using a research
platform with arbitrary biomarker units.
In this current study, we developed a novel high-throughput platform for quantifying
FGF23, used a clinically utilised platform for N-terminal pro-B-type natriuretic peptide (NT-
proBNP), and quantified these biomarkers in the previously tested patients, as well as in an
unselected independent cohort of patients presenting to hospital, for validation. To assess the
predictive power of these biomarkers combined with simple metrics (age, sex, and BMI), we
carefully corrected our associations for known confounders of elevated FGF23 and natriuretic
peptides. As AF screening is aimed at identifying modifiable risks of stroke and other cardio-
vascular complications, we focused our study on patients with CHA2DS2-VASc score of 2 or
more as there is a clear indication for initiation of therapy (e.g., anticoagulation therapy) in
this group of patients.
Methods
Study population
Consecutive patients referred to the Sandwell and West Birmingham Sandwell and West Bir-
mingham NHS Trust (Birmingham, UK) NHS Trust (Birmingham, UK) for inpatient or out-
patient evaluation of acute illnesses were recruited between September 2014 and February
2018 into the Birmingham and Black Country Atrial Fibrillation Registry (BBC-AF Registry).
Patients eligible for recruitment either had diagnosed AF confirmed by ECG, or CHA2DS2-
VASc score of 2 or more. All patients without diagnosed AF underwent 7-day ambulatory
PLOS MEDICINE Validation of an atrial fibrillation biomarker model
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003405 February 3, 2021 3 / 17
Disease; NT-proBNP, N-terminal pro-B-type
natriuretic peptide; ROC, receiver operating
characteristic.
ECG monitoring to exclude silent AF, as previously published [6]. All patients were pheno-
typed: Clinical information was collected during a detailed interview at time of blood sam-
pling, review of electronic patient records, and clinical chart review. ECG and transthoracic
echocardiography were performed in all patients.
In the primary analysis, patients with tachyarrhythmias apart from AF (atrial high rate epi-
sodes, n = 3; atrial flutter, n = 34) were excluded. Sensitivity analyses were performed including
patients with atrial flutter. Using complete cases, we evaluated the performance of the model
in patients whose data had not been used to derive the original model (Fig 1).
Ethics statement
This study complied with the Declaration of Helsinki, was approved by the National Research
Ethics Service Committee (BBC-AF Registry, West Midlands, UK, IRAS ID 97753), and was
Fig 1. Flowchart of patients included in the analysis. A total of 1,084 patients were included in the validation study. Silent or asymptomatic AF patients detected using
7-day ECG monitoring were reassigned to the AF group. Blue boxes indicate the main analysis, orange boxes indicate additional and sensitivity analyses. AF, atrial
fibrillation; BBC-AF registry, Birmingham and Black Country Atrial Fibrillation Registry.
https://doi.org/10.1371/journal.pmed.1003405.g001
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sponsored by the University of Birmingham, UK. All patients provided written informed
consent.
Biomarker quantification
Blood samples from all patients were fractionated and stored at −80˚C until analysis. Absolute
protein concentrations were centrally quantified (Roche Diagnostics, Penzberg, Germany) in
EDTA plasma. NT-proBNP was measured with commercial in vitro diagnostic tests (Elecsys
NT-proBNP II; Roche Diagnostics, Penzberg, Germany) on a cobas Elecsys analyser (Roche
Diagnostics). An immunoassay was developed for detection of FGF23, applying rabbit mono-
clonal antibodies screened for specific analyte detection. The assay reached a functional sensi-
tivity of 4 pg/ml precision and within-run coefficient of variation of 1.7%. Like NT-proBNP,
FGF23 was quantified using this pre-commercial assay on a cobas 6000 Elecsys platform
(Roche Diagnostics). This in vitro diagnostic (IVD) platform is based on electrochemilumines-
cence (ECL) technology for heterogeneous immunoassays, allowing up to 170 tests/hour. For
both biomarkers, the identical plasma sample per blood draw was measured, blinded to clinical
information.
Statistical analysis
Following the initial discovery of FGF23 and NT-proBNP as markers for AF from a pool of 92
cardiovascular biomarkers [6], this analysis was prospectively planned as part of the extended
work plan in the CATCH ME EU-funded project [7] to validate the findings using a high-
throughput assay platform that can be implemented in routine clinical care. While the analyses
were prospectively planned and agreed on between the authors, we did not write a formal sta-
tistical analysis plan.
Baseline characteristics of patients with and without AF were compared. Categorical vari-
ables were assessed using χ2 tests. Continuous variables were compared using independent
samples t tests or Mann–Whitney U tests as applicable after determining data normality (Kol-
mogorov–Smirnov test and visual inspection of descriptive plots). A 2-tailed P value of<0.05
was considered statistically significant. Univariate analyses (adjusted and unadjusted) for
study outcome (rhythm status: AF or no AF) were performed. To fit the current data to the
published model, the model’s beta coefficients and constant were re-estimated to include only
biomarkers whose increase indicated higher odds of having AF. This will improve the practi-
cality of clinical measurement. The re-estimated model consisted of age, sex, BMI, BNP, and
FGF23 (Table A in S1 Text). As the model was derived using BNP, NT-proBNP values were
adjusted by a factor of 3 to approximate the established ratio of rule-out cutoffs in acute heart
failure [8]. The biomarker data were transformed into the log scale (log2) to approximate the
behaviour of the data used to derive the original model. Furthermore, we compared the perfor-
mance of NT-proBNP and FGF23 quantified using Olink and Roche assays, using data from
patients who had biomarkers measured on both platforms.
For validation, the re-estimated model was applied to data from the validation cohort. The
distributions of demographic characteristics of the validation cohort are very similar to those
of the development cohort [6] (Table B in S1 Text). Model performance was evaluated by cal-
culating the Brier score, indicating overall performance, and inspecting the area under the
receiver operating characteristic (ROC) curve (AUC), the corresponding 95% confidence
intervals (CIs), and the elements of a confusion matrix (sensitivity, specificity, positive predic-
tive value [PPV], and negative predictive value [NPV]), which were also evaluated at 4 differ-
ent cutoff points for probability of outcome. In an additional sensitivity analysis, we also
calculated the simple CHARGE-AF model [9,10] for patients in whom all elements of the
PLOS MEDICINE Validation of an atrial fibrillation biomarker model
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11-variable score were available (n = 1,050) and compared its performance to the biomarker
model. We performed sensitivity analyses including patients with atrial flutter, adjusting for
renal function, and adjusting the NT-proBNP cutoffs for AF patients with heart failure.
Results
NT-proBNP and FGF23
In patients with biomarkers quantified on both Olink and Roche platforms (n = 593; Table C
in S1 Text), we found that NT-proBNP and FGF23 values correlated highly between platforms
(NT-proBNP, r = 0.867, p< 0.001; FGF23, r = 0.899, p< 0.001), and variability of the mea-
surements was low (Fig 2).
Of 1,084 patients included in the main analysis, excluding patients used to identify the
model [6], 46% (n = 499) had diagnosed AF. Baseline characteristics indicated that patients
with AF were older and more often had heart failure. The median BMI was in the overweight
category for both groups (Table 1). Both biomarkers were elevated in patients with AF (Fig 3A
and 3B). We also stratified NT-proBNP by heart failure status and FGF23 by renal function
(Fig 3C and 3D). To facilitate comparison of biomarker values with existing studies, we also
report raw biomarker values in picograms/millilitre (Table 1) and present a different visualisa-
tion of the data (Fig A in S2 Text).
We adjusted the univariate association of NT-proBNP with AF to account for heart failure
status, age, sex, and BMI. FGF23 was adjusted by renal function calculated using the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) estimated glomerular filtration rate
Fig 2. Comparison between assays. Values of (a) NT-proBNP and (b) FGF23 measured on the Roche platform highly
correlated with those measured on the Olink platform. (c) Model performance calculated using biomarkers quantified
on both platforms was identical. AUC, area under the receiver operating characteristic curve; NPX, Normalized
Protein eXpression; ROC, receiver operating characteristic.
https://doi.org/10.1371/journal.pmed.1003405.g002
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P value Univariate analysis
odds ratio (95% CI)
Age, years 67 (57, 75) 74 (65, 81) <0.001 1.046 (1.035, 1.058)
Sex male 344 (59%) 300 (60%) 0.66 1.056 (0.828, 1.347)
Ethnicity <0.001
White 422 (72%) 421 (84%) — Reference
Asian 99 (17%) 37 (7%) — 0.375 (0.251, 0.559)
Black 64 (11%) 41 (8%) — 0.642 (0.424, 0.972)
BMI, kg/m2 28.7 (25.0, 32.7) 29.0 (25.1, 32.9) 0.632 1.006 (0.987, 1.024)
Renal function
CKD-EPI 77.0 (57.0, 92.5) 69.0 (50.0, 85.0) <0.001 0.986 (0.981, 0.992)
MDRD 74.1 (24.1) 66.7 (22.4) <0.001 0.989 (0.984, 0.994)
Cockcroft–Gault 80.5 (59.1, 108.0) 68.7(51.1, 98.3) <0.001 0.994 (0.991, 0.997)
CKD by stage (CKD-EPI) <0.001
I 177 (30%) 80 (16%) — Reference
II 248 (42%) 230 (46%) — 2.052 (1.491, 2.824)
IIIa 89 (15%) 93 (19%) — 2.312 (1.561, 3.424)
IIIb 44 (8%) 66 (13%) — 3.319 (2.087, 5.278)
IV 22 (4%) 27 (5%) — 2.715 (1.458, 5.057)
V 5 (1%) 3 (1%) — 1.327 (0.310, 5.691)
Diabetes 266 (46%) 126 (25%) <0.001 0.405 (0.313, 0.525)
Stroke/TIA 51 (9%) 48 (10%) 0.608 1.114 (0.737, 1.685)
Coronary artery disease 307 (53%) 122 (24%) <0.001 0.293 (0.226, 0.380)
Hypertension 368 (63%) 254 (51%) <0.001 0.661 (0.480, 0.779)
Heart failure 249 (43%) 268 (54%) <0.001 1.566 (1.231, 1.991)
Admission criteria (inpatient) 560 (96%) 373 (75%) <0.001 0.132 (0.084, 0.207)
Medication
NOAC 13 (2%) 239 (48%) <0.001 40.466 (22.711, 72.030)
VKA 12 (2%) 122 (24%) <0.001 15.452 (8.421, 28.355)
Aspirin 421 (72%) 129 (26%) <0.001 0.136 (0.104, 0.178)
Antiplatelet agents 331 (57%) 94 (19%) <0.001 0.178 (0.135, 0.235)
ACE inhibitors 247 (42%) 166 (33%) 0.002 0.682 (0.532, 0.874)
Angiotensin II receptor blocker 87 (15%) 90 (18%) 0.16 1.260 (0.912, 1.739)
Beta-blocker 352 (60%) 281 (56%) 0.199 0.853 (0.670, 1.087)
Diuretic 171 (29%) 212 (43%) <0.001 1.788 (1.391, 2.300)
Calcium channel antagonist 134 (23%) 70 (14%) <0.001 0.549 (0.400, 0.755)
Cardiac glycoside 4 (1%) 98 (20%) <0.001 35.498 (12.957, 97.252)
Aldosterone antagonist 33 (6%) 40 (8%) 0.12 1.458 (0.904, 2.349)
Antiarrhythmics 8 (1%) 36 (7%) <0.001 5.608 (2.582, 12.182)
Biomarkers
FGF23 (per 100 pg/ml) 1.55 (1.04, 2.62) 1.93 (1.30, 4.16) <0.001 1.046 (1.022, 1.070)
NT-proBNP (per 100 pg/ml) 4.25 (1.17, 15.70) 12.00 (4.19, 30.15) <0.001 1.006 (1.003, 1.009)
Log2 FGF23 (per 100 pg/ml) 0.64 (0.06, 1.39) 0.95 (0.38, 2.06) <0.001 1.405 (1.275, 1.549)
Log2 NT-proBNP (per 100 pg/ml) 0.56 (2.49) 1.87 (2.25) <0.001 1.258 (1.193, 1.327)
Categorical variables are reported as n (%); continuous variables are reported as mean (standard deviation), or median (quartile 1, quartile 3) for non-parametric
distributions. The independent samples t test (or Mann–Whitney U test for non-parametric distributions) and χ2 tests were used to compare characteristics between
patients.
ACE, angiotensin-converting enzyme; BMI, body mass index; CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; FGF23,
fibroblast growth factor 23; MDRD, Modification of Diet in Renal Disease; NOAC, non–vitamin K antagonist oral anticoagulant; NT-proBNP, N-terminal pro-B-type
natriuretic peptide; TIA, transient ischemic attack; VKA, vitamin K antagonist.
https://doi.org/10.1371/journal.pmed.1003405.t001
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(eGFR) equation, which takes into account age, sex, and ethnicity, and is normalised by body
surface area, using centrally quantified creatinine values obtained in the same plasma sample
as FGF23. The univariate associations between the biomarkers and AF outcome remained sig-
nificant after adjustment (Fig 3E). As a post hoc sensitivity analysis, we also adjusted NT-
proBNP and FGF23 by both heart failure and renal function as these diseases may elevate both
biomarkers (Fig B in S2 Text).
Model validation
The model was applied to data from the validation cohort using the re-estimated coefficients,
and the AUC was 0.688 (95% CI 0.656, 0.719; Fig 4A), with a Brier score of 0.249. This perfor-
mance was very similar to the AUC of the derived model, 0.691 (95% CI0.638, 0.744), with
overlapping confidence intervals indicating a remarkably consistent performance of the model
in the validation cohort.
Fig 3. Description of biomarkers. Both (a) NT-proBNP and (b) FGF23 are significantly elevated in patients with AF.
Stratified biomarker levels indicate that patients with heart failure and impaired renal function have elevated levels of
(c) NT-proBNP and (d) FGF23, respectively. Whiskers represent data between the 1st and 99th percentile, with
outliers in dots. (e) Adjusted and unadjusted univariate associations of biomarkers (odds ratios, 95% confidence
intervals) show significant associations between NT-proBNP, FGF23, and prevalent AF. NT-proBNP levels were
adjusted for age, sex, BMI, and heart failure status. FGF23 levels were adjusted for renal function (estimated
glomerular filtration rate [ml/min/1.73 m2] calculated using the CKD-EPI equation). AF, atrial fibrillation; CKD-EPI,
Chronic Kidney Disease Epidemiology Collaboration; FGF23, fibroblast growth factor 23; NT-proBNP, N-terminal
pro-B-type natriuretic peptide; OR, odds ratio.
https://doi.org/10.1371/journal.pmed.1003405.g003
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From the confusion matrix, the model had a high specificity (96%) and an overall accuracy
of 60% (Fig 4B). When the model was evaluated at different cutoffs, the highest overall predic-
tive accuracy of the tested cutoffs was obtained at 30% (63% accuracy), with a sensitivity of
57% and specificity of 65% (Table 2). The model is presented as a nomogram in Fig 5.
The simple CHARGE-AF model (without echocardiography and ECG variables) [9] was
calculated for 1,057 patients (n = 27 missing data) and compared to the corresponding bio-
marker model for the same patients. The 5-variable biomarker model yielded an AUC of 0.692
(95% CI 0.661, 0.724) in these patients, whereas the 11-variable simple CHARGE-AF model
had a lower AUC of 0.637 (95% CI 0.604, 0.670). Discrimination measures for this comparison
are presented in Fig C in S2 Text.
Sensitivity analysis
Atrial flutter. Atrial flutter is a tachyarrhythmia that often precedes or presents with
AF and is managed with similar goals [11]. Therefore, we investigated the performance of the
biomarkers in patients with atrial flutter (n = 29; n = 5 excluded due to incomplete cases).
Compared to patients in sinus rhythm, both NT-proBNP (p = 0.025) and FGF23 (p< 0.001)
were significantly elevated in patients with atrial flutter (Table D in S1 Text). When patients
with atrial flutter were included in the model validation, the AUC was 0.682 (95% CI 0.651,
Fig 4. Model validation performance. (a) The AUC of the validated model (0.688; 95% CI 0.656, 0.719) closely approximated that of the derived model (0.691; 95% CI
0.638, 0.774). (b) The confusion matrix and performance metrics suggest that the model is highly sensitive in being able to identify sinus rhythm patients to “rule out” AF,
and has an overall accuracy of 60%. AF, atrial fibrillation; AUC, area under the receiver operating characteristic curve; CI, confidence interval; ROC, receiver operating
characteristic; SR, sinus rhythm.
https://doi.org/10.1371/journal.pmed.1003405.g004
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Table 2. Model performance metrics at different cutoffs.
Parameter or prediction Cutoff
10% 20% 30% 40%
Parameter, percent (95% CI)
Sensitivity 96.99 (95.09, 98.31) 82.16 (78.52, 85.42) 56.51 (52.04, 60.91) 35.07 (30.88, 39.44)
Specificity 7.52 (5.52, 9.97) 39.32 (35.34, 43.41) 65.49 (65.49, 73.12) 86.67 (83.64, 89.32)
Positive predictive value 47.22 (46.53, 47.91) 53.59 (51.68, 55.50) 61.17 (57.69, 64.54) 69.17 (63.89, 74.01)
Negative predictive value 74.58 (62.30, 83.89) 72.10 (67.61, 76.19) 65.17 (62.55, 67.70) 61.01 (59.29, 62.71)
Overall accuracy 48.71 (45.69, 51.73) 59.04 (56.05, 61.99) 63.47 (60.52, 66.34) 62.92 (59.96, 65.80)
Predictions by the biomarker model, n
Patients “at risk” 1,025 765 461 253
Identified (“at risk”, with AF) 484 410 282 175
Patients “not at risk” 59 319 623 831
Identified (“not at risk”, no AF) 44 230 406 507
Missed (“not at risk”, with AF) 15 89 217 324
The full model (age, sex, BMI, NT-proBNP, FGF23) was evaluated at 4 cutoff points (probabilities of outcome) that can be used as a decision threshold to identify
patients at risk of prevalent atrial fibrillation (AF). The overall accuracy of the model is maximised when a 30% cutoff is used.
https://doi.org/10.1371/journal.pmed.1003405.t002
Fig 5. Nomogram for the proposed biomarker model. For each patient, points are assigned to each of the 5 variables in the model, which are subsequently totalled to
determine the corresponding risk of atrial fibrillation.
https://doi.org/10.1371/journal.pmed.1003405.g005
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0.714), similar to the model without patients with atrial flutter, with overlapping confidence
intervals.
Renal function. In addition to using the CKD-EPI equation to determine eGFR [12], we
performed a sensitivity analysis using the Modification of Diet in Renal Disease (MDRD)
equation [13] and the Cockcroft–Gault formula [14] to estimate kidney function. The out-
comes of these analyses (Tables 3 and 4) confirm that elevated FGF23 levels remained strongly
associated with AF, demonstrating that the relationship between increased circulating FGF23
and AF persists irrespective of renal function (Fig D in S2 Text).
NT-proBNP cutoffs to detect heart failure in patients with AF
In patients with AF, a higher NT-proBNP threshold value may be more suitable to establish
the presence of concomitant heart failure. The reported ROC-optimised cutoffs for ruling in
heart failure in the age class of this cohort (50–75 years) in acute settings is 900 pg/ml [15]. In
the subcohort of patients with diagnosed AF in the whole BBC-AF Registry (n = 725), we
assessed the ROC curve of NT-proBNP in predicting the outcome of patients with (n = 368) or
without (n = 357) heart failure. Youden’s index was calculated, and the corresponding NT-
proBNP level for the maximum value of the index was 1,070 pg/ml, which is approximately
Table 3. Renal function values using different equations.
Equation Mean or median SD or Q1, Q3
MDRD 71 25
CKD-EPI 73 54, 89
Cockcroft–Gault 75 54, 103
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; MDRD, Modification of Diet in Renal Disease.
https://doi.org/10.1371/journal.pmed.1003405.t003
Table 4. FGF23 levels adjusted by renal function.
Analysis Equation OR 95% CI
No correction FGF23 (per 100 pg/ml; log2) 1.405 1.275, 1.549
FGF23 adjusted by renal function measures MDRD (n = 1,084) 1.364 1.235, 1.506
eGFR > 71 ml/min/1.73 m2 (n = 519) 1.221 1.058, 1.409
eGFR� 71 ml/min/1.73 m2 (n = 565) 1.613 1.382, 1.882
CKD-EPI (n = 1,084) 1.351 1.224, 1.492
eGFR > 73 ml/min/1.73 m2 (n = 527) 1.256 1.083, 1.456
eGFR� 73 ml/min/1.73 m2 (n = 557) 1.566 1.346, 1.821
Cockcroft–Gault (n = 1,084) 1.38 1.251, 1.522
CrCl > 75 ml/min (n = 539) 1.217 1.060, 1.397
CrCl� 75 ml/min (n = 545) 1.549 1.333, 1.801
Whilst both the MDRD and CKD-EPI equations perform well at eGFR < 60 ml/min/1.73 m2, MDRD eGFR is less
accurate at eGFR values� 60 ml/min/1.73 m2, where it tends to underestimate renal function. To avoid potential
biases introduced by the renal function equations and subsequently affecting the adjustment, FGF23 levels were
corrected by MDRD, CKD-EPI, and creatinine clearance equations in patient subcohorts of renal function values
above and below the mean/median for the whole cohort.
CI, confidence interval; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CrCl, creatinine clearance;
eGFR, estimated glomerular filtration rate; FGF23, fibroblast growth factor 23; MDRD, Modification of Diet in Renal
Disease; OR, odds ratio.
https://doi.org/10.1371/journal.pmed.1003405.t004
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170 pg/ml higher than the recommended ROC-optimised cutoffs for ruling in heart failure in
this age category (900 pg/ml) [15].
Discussion
Main findings
Using clinical data and centrally quantified biomarkers in >1,000 unselected patients with car-
diovascular co-morbidities presenting to hospital, our analysis confirmed that the previously
derived model of age, sex, BMI, BNP, and FGF23 identified patients with AF. FGF23 remained
elevated in patients with AF after adjusting for renal function, and NT-proBNP remained ele-
vated after adjusting for heart failure. Considering the high probability of silent or asymptom-
atic AF in the elderly [16], the combination of these 2 biomarkers with simple biometric
information might provide a tool to identify patients who need further workup for diagnosing
AF (Fig 6). Furthermore, these findings may help to better understand the major drivers of AF
in patients.
NT-proBNP as a marker of cardiac overload in AF
The natriuretic peptide BNP and its N-terminal fragment, NT-proBNP, are produced by cardi-
omyocytes in response to pressure and volume increase [17]. Natriuretic peptide quantifica-
tion is clinically used to rule out heart failure [8,18], and elevated levels have been associated
Fig 6. Validation of a biomarker model for predicting prevalent AF. Identifying patients with AF to improve screening yield and initiate stroke prevention therapy is an
important clinical challenge. We propose the use of a model comprising 3 simple characteristics (age, sex, and BMI) combined with 2 biomarkers (NT-proBNP and
FGF23) to identify patients with prevalent AF. AF, atrial fibrillation; OR, odds ratio.
https://doi.org/10.1371/journal.pmed.1003405.g006
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with other cardiovascular conditions. In our prior analysis using a discovery biomarker
screening platform, BNP was clearly elevated in patients with AF and emerged as 1 of the 2
strongest out of 92 biomarkers [6]. This finding is highly consistent with prior studies identify-
ing a clear association between AF and elevated natriuretic peptides for predicting imminent
AF episodes in patients with paroxysmal AF [19], which has led to testing of natriuretic pep-
tides to guide detection of undiagnosed AF [20], and to inform risk stratification and therapy
selection in patients with AF [21,22]. In our validation study, we found that NT-proBNP levels
in patients with AF, quantified using standardised, absolute NT-proBNP values, had compara-
ble ORs to the development cohort. The consistency of the presence and magnitude of the
associations provides further evidence of the utility of natriuretic peptides for discriminating
between patients with and without AF.
Having concomitant AF and heart failure has implications for diagnostic and prognostic
performance of NT-proBNP [23]. In our study, clear effects remained after adjusting NT-
proBNP for heart failure status, illustrating that both heart failure and AF lead to elevated
natriuretic peptides. However, the elevation of NT-proBNP by itself was inadequate to distin-
guish between heart failure and AF. When we evaluated NT-proBNP cutoffs at 152 pg/ml (5th
percentile) and 269 pg/ml (10th percentile) in patients with heart failure and AF (n = 268) in
comparison with the recommended cutoff of<125 pg/ml, the recommended cutoff accurately
ruled out heart failure in all patients with AF, whereas higher thresholds were less accurate
(Table E in S1 Text). This outcome suggests that the current cutoff value for NT-proBNP
(<125 pg/ml) is useful in the context of a point-of-care test for further workup as low NT-
proBNP values may be able to rule out both AF and heart failure, which have overlapping risk
factors and pathophysiologies [24].
Validation of FGF23 as a marker of AF
The circulating hormone FGF23 is best known as a phosphaturic hormone, with serum levels
rising exponentially in chronic kidney disease (CKD), including in the early stages of CKD
[25]. Elevated FGF23 is associated with all-cause and cardiovascular mortality [26,27] and with
heart failure [26] in patients with or without CKD. In in vitro and in vivo studies, FGF23 has
been directly implicated in the development of cardiac hypertrophy [28] and fibrosis [29].
This study validated our prior hypothesis-generating finding that elevated FGF23 increases the
odds of prevalent AF. Using a newly developed near-routine, high-throughput, high-sensitivity
assay for FGF23 in this validation, we showed that elevated FGF23 in patients with AF is inde-
pendent of renal function (Tables 3 and 4). Elevated FGF23 has been associated with left ven-
tricular dysfunction and AF in patients without cardiovascular co-morbidities [30], including
incident AF after correction for eGFR, albuminuria, and heart failure events [31], and con-
firmed in patients with CKD [32]. Higher levels of circulating FGF23 were associated with
greater odds of incident AF [32]. Coincidentally, our data showed that patients with eGFR and
creatinine clearance below the cutoffs (MDRD eGFR� 71 ml/min/1.73 m2; CKD-EPI
eGFR� 73 ml/min/1.73 m2; creatinine clearance� 75 ml/min; Tables 3 and 4) have greater
odds of having AF, and the cutoffs are around the level at which FGF23 is thought to rise [25].
FGF23 concentrations were similar in patients in sinus rhythm with CKD (CKD-EPI
eGFR< 60 ml/min/1.73 m2) and in those with AF and normal renal function (Fig 3D). This
observation persisted when applying a higher eGFR threshold or using different eGFR equa-
tions (Fig D in S2 Text). FGF23 has been identified to stimulate cardiac remodelling via spe-
cific myocardial FGF23-receptor activation. However, this mechanism has been suggested to
be independent from alpha-Klotho, which is a co-receptor for FGF23-mediated regulation of
mineral metabolism [33]. The failing heart can also be a major source of circulating FGF23,
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and patients who experience recurrent AF 6 months after AF ablation were observed to have
greater left atrial FGF23 levels and lower soluble Klotho than patients with normal renal func-
tion [34,35].
Potential value for detecting patients with AF
Early detection of AF is crucial for initiation of anticoagulation prior to a first stroke [11] and
risk factor management to reduce AF burden [36]. The combination of easily established clini-
cal characteristics and circulating blood biomarkers that can be rapidly quantified presents an
important opportunity for point-of-care testing for AF. Both routine and acute presentations
to hospital are advantageous moments for patients to be tested and immediately referred for
further monitoring where necessary. In these settings, biomarkers can be helpful in identifying
at-risk patients [37] who would benefit from prolonged ECG monitoring. Existing models
such as CHARGE-AF, require a large number of variables to calculate, some of which require
specialist input, e.g., clinical determination of heart failure. As such, a simple model using age,
sex, and BMI and a blood sample for biomarker quantification presents an opportunity to
accelerate screening efforts, which in our cohort demonstrated better performance than
CHARGE-AF. As AF can be driven by different underlying mechanisms [7], it is important
for future work to consider multibiomarker models, including novel markers (e.g., cancer anti-
gen 125) [38], in the effort to improve AF detection. In contrast to the research assay platform
used in model development, the current high-sensitivity assays validated in this study can be
run on routine high-throughput machines already available in many testing labs for immedi-
ate, large-scale clinical application.
Limitations
This validation study was performed in patients recruited using similar criteria as the cohort
included in model derivation. While the inclusion criteria were broad and the setting in a gen-
eral hospital resembles clinical routine in many healthcare systems, thus suggesting that our
findings are generalisable, further validation is desirable. Importantly, all patients in this
cohort will have a clear indication for oral anticoagulation should they be diagnosed with AF,
rendering them a population in whom screening is clinically useful. Our associations, while
supporting intriguing mechanistic hypotheses, cannot be used to infer causation. Further stud-
ies should evaluate whether elevated NT-proBNP and FGF23 contribute to AF mechanistically
or whether they are markers for other disease processes. In addition, although the model was
developed for identifying prevalent AF cases, the high specificity of this model suggests that
the model might be suited for ruling out non-AF cases. This consideration warrants further
analysis for determination of appropriate cutoffs, which is beyond the scope of the current
work.
Conclusions
In this validation study, we demonstrated the consistency of a model combining simple char-
acteristics (age, sex, and BMI) with the biomarkers NT-proBNP and FGF23 to identify patients
for further ECG monitoring. The model performed reliably despite potential variability intro-
duced by using different biomarker assays and different natriuretic peptide fragments from
those used in the original model. Clear elevations of NT-proBNP and FGF23 remained after
rigorous adjustment for known confounders. The outcomes of this study support the use of a
multibiomarker model in identifying AF as AF can be driven by different mechanisms. Further
validation of this model in different patient cohorts and further basic science investigation into
the molecular mechanisms of NT-proBNP and FGF23, especially in the context of AF and co-
PLOS MEDICINE Validation of an atrial fibrillation biomarker model
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morbid heart failure or CKD, would be useful to validate this finding and to understand the
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